Neuroimaging, Biomarkers, and Management of Dementia with Lewy Bodies

Overview

Journal Front Neurol

Specialty Neurology

Date 2013 Oct 11

PMID 24109473

Citations 4

Authors

Hasmet A Hanagasi

Basar Bilgic

Murat Emre

Affiliations

Soon will be listed here.

Citing Articles

Biomarkers in Alzheimer's, Frontotemporal, Lewy Body, and Vascular Dementias.

Koenig A, Nobuhara C, Williams V, Arnold S Focus (Am Psychiatr Publ). 2020; 16(2):164-172.

PMID: 31975911 PMC: 6526853. DOI: 10.1176/appi.focus.20170048.

Biomarkers for the diagnosis of Alzheimer's disease, dementia Lewy body, frontotemporal dementia and vascular dementia.

Maclin J, Wang T, Xiao S Gen Psychiatr. 2019; 32(1):e100054.

PMID: 31179427 PMC: 6551430. DOI: 10.1136/gpsych-2019-100054.

Neurophysiological biomarkers for Lewy body dementias.

Cromarty R, Elder G, Graziadio S, Baker M, Bonanni L, Onofrj M Clin Neurophysiol. 2015; 127(1):349-359.

PMID: 26183755 PMC: 4727506. DOI: 10.1016/j.clinph.2015.06.020.

Genetic markers in biological fluids for aging-related major neurocognitive disorder.

Castro-Chavira S, Fernandez T, Nicolini H, Diaz-Cintra S, Prado-Alcala R Curr Alzheimer Res. 2015; 12(3):200-9.

PMID: 25731625 PMC: 4443795. DOI: 10.2174/1567205012666150302155138.

References

Kantarci K, Ferman T, Boeve B, Weigand S, Przybelski S, Vemuri P . Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology. 2012; 79(6):553-60. PMC: 3413765. DOI: 10.1212/WNL.0b013e31826357a5. View

Hu X, Okamura N, Arai H, Higuchi M, Matsui T, Tashiro M . 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology. 2000; 55(10):1575-7. DOI: 10.1212/wnl.55.10.1575. View

Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M . EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain. 2008; 131(Pt 3):690-705. DOI: 10.1093/brain/awm322. View

Kenny E, Blamire A, Firbank M, OBrien J . Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer's disease. Brain. 2011; 135(Pt 2):569-81. PMC: 3708629. DOI: 10.1093/brain/awr327. View

McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J . Dementia with Lewy bodies. Lancet Neurol. 2003; 3(1):19-28. DOI: 10.1016/s1474-4422(03)00619-7. View

McKeith I, del Ser T, Spano P, Emre M, Wesnes K, Anand R . Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2001; 356(9247):2031-6. DOI: 10.1016/S0140-6736(00)03399-7. View

Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K . Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009; 8(7):613-8. DOI: 10.1016/S1474-4422(09)70146-2. View

Firbank M, Colloby S, Burn D, McKeith I, OBrien J . Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage. 2003; 20(2):1309-19. DOI: 10.1016/S1053-8119(03)00364-1. View

Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K . CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2010; 82(2):160-4. DOI: 10.1136/jnnp.2009.199398. View

10.

Mori E, Ikeda M, Kosaka K . Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012; 72(1):41-52. PMC: 3504981. DOI: 10.1002/ana.23557. View

11.

Lucetti C, Logi C, Del Dotto P, Berti C, Ceravolo R, Baldacci F . Levodopa response in dementia with lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord. 2010; 16(8):522-6. DOI: 10.1016/j.parkreldis.2010.06.004. View

12.

Bozzali M, Falini A, Cercignani M, Baglio F, Farina E, Alberoni M . Brain tissue damage in dementia with Lewy bodies: an in vivo diffusion tensor MRI study. Brain. 2005; 128(Pt 7):1595-604. DOI: 10.1093/brain/awh493. View

13.

Raedler T . Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry. 2010; 23(6):574-81. DOI: 10.1097/YCO.0b013e32833f46c9. View

14.

Molloy S, McKeith I, OBrien J, Burn D . The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005; 76(9):1200-3. PMC: 1739807. DOI: 10.1136/jnnp.2004.052332. View

15.

Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, DAmore C . Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry. 2008; 64(10):850-5. DOI: 10.1016/j.biopsych.2008.02.016. View

16.

Burton E, Mukaetova-Ladinska E, Perry R, Jaros E, Barber R, OBrien J . Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia. Neurobiol Aging. 2011; 33(7):1228-36. DOI: 10.1016/j.neurobiolaging.2010.12.015. View

17.

Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro T, Pepivani I . Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008; 213(2):315-25. DOI: 10.1016/j.expneurol.2008.06.004. View

18.

Postuma R, Gagnon J, Montplaisir J . REM sleep behavior disorder: from dreams to neurodegeneration. Neurobiol Dis. 2011; 46(3):553-8. DOI: 10.1016/j.nbd.2011.10.003. View

19.

Lobotesis K, Fenwick J, Phipps A, Ryman A, Swann A, Ballard C . Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology. 2001; 56(5):643-9. DOI: 10.1212/wnl.56.5.643. View

20.

Albin R, Minoshima S, DAMATO C, Frey K, Kuhl D, Sima A . Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996; 47(2):462-6. DOI: 10.1212/wnl.47.2.462. View